0001689813-19-000071.txt : 20191025 0001689813-19-000071.hdr.sgml : 20191025 20191025203951 ACCESSION NUMBER: 0001689813-19-000071 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191018 FILED AS OF DATE: 20191025 DATE AS OF CHANGE: 20191025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stock Elyse CENTRAL INDEX KEY: 0001785732 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 191171014 BUSINESS ADDRESS: BUSINESS PHONE: (203) 404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 wf-form4_157205036147621.xml FORM 4 X0306 4 2019-10-18 0 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001785732 Stock Elyse C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET NEW HAVEN CT 06510 0 1 0 0 Chief Medical Officer Common Shares 2019-10-18 4 M 0 17700 10.82 A 17700 D Common Shares 2019-10-18 4 S 0 17700 45.0706 D 0 D Employee Stock Option (Right to Buy) 10.82 2019-10-18 4 M 0 17700 0 D 2027-04-05 Common Shares 17700.0 18500 D These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 - $45.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The option, representing a right to purchase a total of 37,000 shares, became exercisable as to 18,500 shares on and prior to April 6, 2019 and becomes exercisable as to the remaining 18,500 shares on April 6, 2020, subject to the reporting person's continued service as of such date. The Reporting Person previously exercised the option with respect to 800 shares on October 15, 2019. /s/ Jim Engelhart, Attorney-in-fact 2019-10-25